Clinomics Europe Kft.

Clinomics Europe was founded in Budapest in 2021 as an innovative medical biotechnology company specializing in multiomics-based precision medicine and oncology. We develop and deploy next-generation molecular diagnostic tools using cutting-edge technologies, including liquid biopsy, next-generation sequencing (NGS), real-time qPCR, and digital PCR (dPCR).

Minimally invasive and repeatable methods, such as liquid biopsy, offer major advantages over traditional gold-standard techniques in oncology. They enable early diagnosis, real-time monitoring, and longitudinal assessment of therapy effectiveness. Blood-based biomarkers, including circulating tumor cells (CTCs) and cell-free DNA and RNA, are emerging as more sensitive and specific alternatives to traditional biomarkers. By integrating liquid biopsy with advanced molecular technologies such as NGS, qPCR, and dPCR, we aim to elevate precision medicine to a new level. 

Building on our research expertise, we launched Clinomics Diagnostics, our dedicated molecular genetic diagnostics division, in 2023. This innovative initiative seeks to reduce the burden of major diseases across Europe by using unique, liquid biopsy–based molecular tests that detect diseases at their earliest stages.

Among these is ColonAiQ, a revolutionary DNA-based blood test designed for the early detection of colorectal cancer (CRC). ColonAiQ not only identifies the presence of cancer with high sensitivity but may also detect precancerous polyps years before they become malignant. By enabling action before symptoms appear, ColonAiQ could dramatically enhance prevention and early intervention outcomes.

Moreover, we offer a wide range of R&D services, providing customized liquid biopsy–based solutions tailored to specific research projects. We also supply a broad selection of laboratory instruments and reagents to support molecular diagnostic applications.

🔗 Learn more:

www.clinomicseurope.com

www.clinomicsdiag.hu